Diamyd Medical AB Reports Promising Safety Findings from Phase I Study in Chronic Pain

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Diamyd Medical AB (STO:DIAMB): To date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.